Kiniksa Pharmaceuticals International PLC
KNSAHealthcare|Drug Manufacturers - Specialty & Generic|UK
$63.44
-1.91 (-2.92%)
DCF (FCF)
$4.91
Tangible Book
$7.70
Graham Number
$12.49
About
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States.
Stock Price
+119.1%(1Y)
Pipeline Summary
10 total trials1
Phase 1
7
Phase 2
3
Phase 3
0
Phase 4
Completed: 6Recruiting: 2Active: 1Terminated: 1
Active Trials (3)
Transition to KPL-387 Monotherapy Dosing & Administration Study
NCT07288216Recurrent Pericarditis
Phase 2Recruiting
Enrollment: 80 participants
REgiStry Of the NAtural History of recurreNt periCarditis in pEdiatric and Adult Patients
NCT04687358Recurrent Pericarditis
Active
Enrollment: 500 participants
Phase 2/3 Study of KPL-387 in Recurrent Pericarditis
NCT07010159Pericarditis
Phase 2Phase 3Recruiting
Enrollment: 165 participants
BioScore
4.9/10
Cautious
Ownership
Recent Insider Trades
Patel Sanj KSELL
2026-05-0148,565 shares @ $54.02
Paolini John F.SELL
2026-05-0158,424 shares @ $53.71
Patel Sanj KSELL
2026-04-30508,339 shares @ $51.96
Quart Barry DSELL
2026-04-2813,099 shares @ $50.1
Megna Michael RSELL
2026-04-096,625 shares @ $46.69
Recent News
2026-07-13 12:39:22
2026-07-08 00:26:33
2026-06-29 23:51:53
2026-06-29 14:06:25
2026-06-26 00:11:23
Data last updated: Jul 13, 2026, 12:40 PM